Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMOB3CI)

Drug Name
ALXN1720 Drug Info
Synonyms gefurulimab
Indication
Disease Entry ICD 11 Status REF
Generalized myasthenia gravis 8C60 Phase 3 [1]
Cross-matching ID
TTD Drug ID
DMOB3CI

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Complement C5 (CO5) TTKANGO CO5_HUMAN Not Available [2]

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Generalized myasthenia gravis
ICD Disease Classification 8C60
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Complement C5 (CO5) DTT C5 7.69E-01 -0.12 -0.23
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 ClinicalTrials.gov (NCT05556096) A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel, Multicenter Study to Evaluate the Safety and Efficacy of ALXN1720 in Adults With Generalized Myasthenia Gravis. U.S.National Institutes of Health.
2 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2023. Adis Insight